<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>admin on data_fR@</title>
    <link>/authors/admin/</link>
    <description>Recent content in admin on data_fR@</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 01 Nov 2018 00:00:00 +0200</lastBuildDate>
    
	<atom:link href="/authors/admin/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model.</title>
      <link>/publication/gvhd-model/</link>
      <pubDate>Thu, 01 Nov 2018 00:00:00 +0200</pubDate>
      
      <guid>/publication/gvhd-model/</guid>
      <description>In this article we describe the development and simulation of a decision model for the second-line treatment of acute GvHD.</description>
    </item>
    
    <item>
      <title></title>
      <link>/author/admin/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>/author/admin/</guid>
      <description>Frederick W. Thielen is a PhD student in Health Technology Assessment (HTA) at the Erasmus University Rotterdam (The Netherlands). His research interests include health economic modelling of haematological diseasesas well as pharmaceutical pricing and market access of new (and therefore mostly [very] expensive) cancer drugs.
Whenever possible, he is conducting his research in R and is guided by following principle:
1) Did you do it in R?
2) If not, how can you do it in R?</description>
    </item>
    
  </channel>
</rss>